How Scientists Are Redesigning LL-37 to Create Better Antimicrobial Peptide Drugs
A comprehensive review of how researchers are modifying the human antimicrobial peptide LL-37 to overcome its limitations and develop it into a viable treatment for drug-resistant infections.
Quick Facts
What This Study Found
This comprehensive review examines how scientists have modified LL-37 — the only human cathelicidin antimicrobial peptide — to overcome its key limitations: high production costs, reduced effectiveness under real physiological conditions, vulnerability to enzymatic breakdown, and toxicity to human cells.
Multiple modification strategies have improved LL-37's clinical potential, including truncation (shortening the peptide while keeping its active region), amino acid substitutions, cyclization, and conjugation with nanocarrier delivery systems. Modified LL-37 derivatives show enhanced activity against bacterial biofilms and cell membranes, and some demonstrate synergy with traditional antibiotics.
Key Numbers
How They Did This
Narrative review of the scientific literature on LL-37 modification techniques, structure-activity relationships, mechanisms of action, nanocarrier delivery systems, and clinical application status.
Why This Research Matters
Antibiotic resistance is one of the biggest threats to modern medicine, and antimicrobial peptides like LL-37 represent a fundamentally different approach to fighting infections. Unlike conventional antibiotics that target specific bacterial processes, LL-37 physically disrupts bacterial membranes — making it harder for bacteria to develop resistance. This review maps the path from a promising natural peptide to potentially viable clinical treatments.
The Bigger Picture
With antibiotic-resistant superbugs becoming a growing global health crisis, antimicrobial peptides are attracting intense research interest as a new class of anti-infective drugs. LL-37 is especially promising because it's a natural part of human immunity, but turning it into an actual medication requires solving real engineering challenges. This review shows how close — and how far — we are from LL-37-based drugs.
What This Study Doesn't Tell Us
As a review article, this synthesizes existing research rather than generating new data. The clinical translation of most LL-37 derivatives is still in early stages, and many findings come from in vitro or animal studies.
Questions This Raises
- ?Which LL-37 modification strategy offers the best balance of antimicrobial potency, safety, and manufacturing cost?
- ?Can LL-37 derivatives combined with traditional antibiotics help rescue drugs that bacteria have already become resistant to?
- ?How will nanocarrier delivery systems affect the pharmacokinetics and tissue targeting of LL-37 derivatives in humans?
Trust & Context
- Key Stat:
- Only human cathelicidin LL-37 is the only cathelicidin antimicrobial peptide produced by the human body, making it a natural starting point for developing new anti-infective therapies
- Evidence Grade:
- This is a review article that synthesizes findings from many individual studies. It provides a comprehensive overview of the field but does not generate new experimental data. The evidence quality of the underlying studies varies from in vitro to early clinical work.
- Study Age:
- Published in 2025, this review captures the latest developments in LL-37 derivative research including recent nanocarrier delivery advances and clinical translation efforts.
- Original Title:
- Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.
- Published In:
- ACS biomaterials science & engineering, 11(6), 3145-3164 (2025)
- Authors:
- Yuan, Yihao, Li, Jiapeng, Wei, Guotao, Shen, Ziyi, Li, Bo, Wu, Jiawei, Liu, Jing
- Database ID:
- RPEP-14429
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is LL-37 and why is it important?
LL-37 is the only antimicrobial peptide in the cathelicidin family that the human body produces. It's part of your innate immune system and works by physically disrupting bacterial cell membranes. It can kill a wide range of bacteria, including drug-resistant strains, and also breaks up biofilms — the protective layers bacteria form on surfaces like wounds and medical implants.
Why can't LL-37 be used as a drug in its natural form?
Natural LL-37 has several problems that prevent direct clinical use: it's expensive to manufacture, enzymes in the body break it down quickly, it loses effectiveness in the salt-rich environment of human tissues, and at the concentrations needed to kill bacteria, it can also damage human cells. That's why researchers are modifying its structure to keep the antimicrobial activity while fixing these limitations.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-14429APA
Yuan, Yihao; Li, Jiapeng; Wei, Guotao; Shen, Ziyi; Li, Bo; Wu, Jiawei; Liu, Jing. (2025). Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.. ACS biomaterials science & engineering, 11(6), 3145-3164. https://doi.org/10.1021/acsbiomaterials.4c02029
MLA
Yuan, Yihao, et al. "Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.." ACS biomaterials science & engineering, 2025. https://doi.org/10.1021/acsbiomaterials.4c02029
RethinkPeptides
RethinkPeptides Research Database. "Exploring the Antimicrobial Potential of LL-37 Derivatives: ..." RPEP-14429. Retrieved from https://rethinkpeptides.com/research/yuan-2025-exploring-the-antimicrobial-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.